Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Monoclonal antidobies |
| Generic Name : | Alemtuzumab |
| Drug description : | Concentrate for solution for infusion in 3ml ampoules. |
| Presentation : | Infusion, alemtuzumab 30mg (10mg/ml) |
| Indications : | Treatment of patients with chronic lymphocytic leukaemia who have been treated with alkyating agents and who have failed to achieve a complete or partial response or achieved only a short remission (less than six months) following fludarabine phosphate therapy. |
| Adult Dosage : | Recommended dose, 3mg on day one, then 10mg on day two and 30mg on day three, assuming each dose is well tolerated. Then 30mg daily three times a week, on alternate days, up to a maximum treatment period of 12 weeks. All doses should be administered by intravenous infusion over approximately two hours. |
| Child Dosage : | Under 17 years, not recommended |
| Contra Indications : | Active systemic infections, HIV, active secondary malignancies, renal or heptic impairment. Hypersensitivity or anaphylactic reactions to alemtuzumab, to murine proteins or to any of the excipients. Pregnancy; males and females of childbearing potential should use effective contraceptive measures during treatment and for six months following therapy. Lactation, discontinue during treatment and for at least four weeks following therapy. |
| Special Precautions : | Should be administered under the supervision of a physician experienced in the use of cancer therapy. Administer an appropriate antihistamine and analgesic prior to the first dose, at easch escalation, and prior to subsequent infusions, as clinically indicated. Administer antibiotics if there is evidence of disease progression. Dose must be well tolerated prior to further escalation. Re-perform gradual dose escalation if therapy is withheld for more than seven days. Interrupt treatment if serious infection or severe haematological toxicity occurs. Elderly, ischaemic heart disease, angina, patients receiving antihypertensive medication. Perform complete blodd counts and platelet counts regularly and more frequently in patients who develop cytopenias. |
| Interactions : | Should not be given within three weeks of other chemotherapeutic agents. Allow 12 months before administering live vaccines. |
| Adverse Reactions : | Very commonly, rigors, fever, fatigue, anorexia, hypotension, headache, vomiting, nausea, diarrhoea, sepis, herpes, simplex, pneumonia, dyspnoea, urticaria, rash, pruritus, increased sweating. Also haematological changes, injection site reactions, other infections, pain, oedema, asthenia, malaise, cardiovascular and respiratory effects, skin reactions, confusion, anxiety, somnolence, depression, insomnia, arthralgia, myalgia, weight loss, hypocalcaemia, thirst, hyponatraemia, gastrointestinal disturbance, hepatic dysfunction, taste loss, tremor, hypoaesthesia, dizziness, hyperkinesia, conjunctivitis, paraesthesia, vertigo. |
| Manufacturer : | Schering Health Care |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org